40 results about "Urothelial cancer" patented technology

This invention relates to a method for detecting in vitro a urothelial cancer, comprising measuring CXCL1 protein, or expression of a gene encoding the protein, in a biological sample from a subject, and to a kit for diagnosing a urothelial cancer comprising an antibody or nucleic acid probe, which is capable of binding specifically to the CXCL1 protein or a gene encoding the protein, respectively.

The present invention is directed to methods and kits useful for diagnosis and / or prognosis of urothelial cancer in a subject. The present invention further relates to methods of assessing severity of cancer and methods of determining efficacy of a treatment for cancer. The methods and kits of the invention comprise determining the levels of semaphorin 3A in a biological sample of a subject.

New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phendtypic variables with levels of genotypic expression into a new metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC.

The present invention concerns a quantitative in situ assessment of mean telomere length, particularly in relation to nuclear area, for the diagnosis and / or prognosis of cancer. In particular aspects, the methods and compositions regard diagnosis and / or prognosis of bladder cancer, urothelial cancer, lung cancer, and lymphoma.

Methods for the treatment of patients with HER2-positive, HER2-amplified and / or HER2-mutated advanced cancer by administration of pertuzumab plus trastuzumab are disclosed. In one aspect, the cancer is advanced HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer that is refractory to one or more other treatment regimens.

The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg / kg and 18 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg, most preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer.

The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).

The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.

The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and / or maintenance therapy.

The invention relates to aminopyrimidopyrazole / pyrrole derivatives, a preparation method and application thereof, and belongs to the field of medicine. The present invention provides the compound represented by formula I, its optical isomer, and the pharmaceutically acceptable salt of the compound or its optical isomer. Biological experiments have proved that the compound of the present invention can not only significantly inhibit the proliferation of breast cancer, lung cancer, colorectal cancer, gastric cancer, bile duct cancer, urothelial cancer and other cancer cells, but also has a broad-spectrum anti-cancer effect, and has a broad-spectrum anti-cancer effect. The proliferation of cells and hepatic stellate cells also showed inhibitory effect, and could inhibit tumor growth in vivo, providing a new option for the development of anti-tumor and anti-fibrotic drugs.

The present invention provides a compound with benzyloxy aromatic ring structure represented by general formula (I), its stereoisomer, enantiomer or pharmaceutically acceptable salt thereof, its preparation method, and its pharmaceutical combination objects and their uses. The compound represented by the general formula (I) can be used to prepare small molecule inhibitors of PD1 / PD-L1 interaction, which can be used to prevent and / or treat diseases related to PD1 / PD-L1 interaction, especially cancer , such as, inter alia, non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, locally advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell carcinoma, prostate cancer Carcinoma, liver cancer, colon cancer, gastric cancer, multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma liver cancer, Hodgkin's lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and other cancers.

Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

The invention relates to aminopyrimidopyrazole / pyrrole derivatives, a preparation method and application thereof, and belongs to the field of medicine. The present invention provides compounds of formula I, stereoisomers thereof, and pharmaceutically acceptable salts of compounds or stereoisomers thereof. Biological experiments have proved that the compound of the present invention can not only significantly inhibit the proliferation of breast cancer, lung cancer, gastric cancer, bile duct cancer, urothelial cancer and other cancer cells, but also has a broad-spectrum anti-cancer effect. The proliferation of tumor cells also showed inhibitory effect, and it can inhibit the growth of tumors in vivo, which provides a new option for the development of anti-tumor, anti-lung and liver fibrosis drugs.

The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.

The present invention is directed to methods and kits useful for diagnosis and / or prognosis of urothelial cancer in a subject. The present invention further relates to methods of assessing severity of cancer and methods of determining efficacy of a treatment for cancer. The methods and kits of the invention comprise determining the levels of semaphorin 3A in a biological sample of a subject.